a large interindividual variability in the degree of drug interaction between patients. Background. Cyclosporin (CsA) is metabolized primarily in the liver by cytochrome P-450 enzymes. Conclusions. Fluconazole given orally in a dose of 200 mg/day is associated with significant increase in Concomitant use of fluconazole can increase CsA concentrations by inhibiting this enzyme system and bioavailability of CsA. The maximum effect occurs on day 4 after starting fluconazole. Although repeated the effect seems to be dose dependent, with no interaction noted when fluconazole is used in a dose of monitoring of CsA C min is convenient as opposed to repeated determination of AUC, changes in C min may 100 mg/day. Two previous investigations studying this interaction while using higher doses of fluconazole not be sensitive enough to pick up this interaction.
after starting fluconazole orally in a dose of Introduction 200 mg/day. From day 8 onwards, patients reduced CsA dose by 50% and the above parameters were Cyclosporin (CsA), continues to be widely used in repeated on day 14. most immunosuppressive regimens to prevent allograft Results. CsA AUC increased from 2887±1729 rejection in patients after solid organ transplantation. ng.h/ml on day 0 to 3842±1975 ng.h/ml on day 2 However this drug is bestowed with a narrow thera-(P<0.05), 4750±1718 ng.h/ml on day 4 (P<0.01) and peutic range and there is marked inter-individual and then decreased to 4052±1687 ng.h/ml on day 7 intra-individual variability in terms of the blood levels (P<0.01). Following CsA dose reduction by 50%, achieved after a given dose [1, 2] . The use of microethe mean AUC decreased significantly to mulsified preparation of the drug has minimized the 2330±1602 ng.h/ml (P<0.01). The C max showed a intra-individual variability in absorption of the drug significant increase from 701±345 ng/ml on day 0 to resulting in more predictable blood levels and dose 941±326 ng/ml (P<0.01) on day 4 but decreased from linearity in bioavailability [3] . CsA is metabolized 768±292 ng/ml on day 7 to 498±289 ng/ml on day primarily in the liver by cytochrome P-450 group of 14, P<0.01. The mean C min increased from enzymes, in particular the CYP3A4 [4] ; drugs that 207±138 ng/ml on day 0 to 274±168 ng/ml on day 4. stimulate or inhibit this enzyme system can significantly No significant changes were observed in CsA clearance alter bioavailability of the drug. and T max.
On repeated-measurement ANOVA, only Fungal infections are not uncommon after renal the AUC and C max on day 4 of fluconazole were transplantation and systemic fungal infections are assosignificantly higher than day 0 (P<0.001). There was ciated with a high mortality [5] . Current options for treating serious fungal infections include systemic amphotericin B, flucytosine or the imidazole group of is the drug of choice for serious fungal infections, it gations including CsA levels were repeated on days 2, 4 and requires weeks of intravenous administration and can proportions. This group of drugs, in particular fluconparent CsA molecule. The mean inter-assay and intra-assay azole, is routinely used for prophylaxis against fungal coefficients of variation using this kit at our laboratory are infections in many centres, especially after liver and 6.8% and 4.3% respectively.
bone marrow transplantation (BMT ).
Routine CsA trough level monitoring is not practised at
Fluconazole produces less marked inhibition of hep-this centre because of financial constraints and this is only atic cytochrome P-450 enzyme CYP3A4 as compared performed when clinically indicated. Patients exhibiting a to ketoconazole, at least in vitro [6, 7] . The potential rise in serum creatinine more than 20% above their baseline interaction of oral fluconazole 200 mg/day with CsA value during the course of the study were required to be was systematically studied in a randomized double removed from the study protocol and undergo a graft biopsy. blind placebo controlled trial by Canafax et al. [8] The results of CsA blood levels in these patients were to be made available to the treating clinician on request. In the who concluded that CsA trough levels almost doubled absence of any graft dysfunction, the results of CsA blood after 1 week and CsA clearance decreased by an levels were available to the clinician only after completion average of 55%. However, because bioavailability of of the study protocol. Based on available literature, before
CsA is known to show a considerable inter-individual the study was planned, it had been the practice at this centre variation, the study design can be faulted and a cross-to reduce CsA dose by 50% after a week of treatment with over design where the patient acts as his own control, 200 mg or more of oral fluconazole a day. All patients were would be preferable in this situation. Moreover, a enrolled after obtaining informed consent, and had the recent prospective trial on BMT patients receiving option to withdraw from the study protocol whenever they intravenous CsA and high dose intravenous flucona-desired. The study protocol had the sanction of the Ethics zole concluded that the drug interaction was not of Committee of the Institute. drug. The maximum blood concentration (C max ) was determined by observation of each patient's data; and T max was the time that C max first occurred. C min was the concentration
Subjects and methods
of CsA in blood drawn just before ingestion of the CsA dose. CsA clearance was calculated using the formula: Six renal transplant recipients on CsA immunosuppression with stable graft functions for at least 2 weeks (defined as a Clearance(ml/m/kg)= CsAdose(ng)×1440min C min (ng/ml )×Ideal body weight (kg) change in serum creatinine of <20%) were studied in a prospective, unblinded, crossover trial. All patients had evidence of systemic candidiasis requiring anti-fungal treatPaired t test was used to assess the differences in serum ment. Only patients on microemulsified preparation of creatinines, CsA AUC, C max , C min , CsA clearance, and T max CsA (Sandimmun Neoral, Novartis Pharma AG, Basel, with and without fluconazole and after 50% CsA dose Switzerland), who had not had any alteration in CsA dosages reduction. Factorial analysis was done using the SPSS (verin the previous 2 weeks were included. Patients having sion 6) computer software program to test any interaction received in the previous 2 weeks any drug known to potenti-between CsA AUC, C max , C min and CsA clearance with time. ate the nephrotoxicity of CsA or those with planned Repeated measurement ANOVA was performed to test for co-administration of any other drug known to interfere with intra-individual variability in these parameters with time. CsA pharmacokinetics were excluded. Patients with histories Only P values <0.05 were considered significant. of acute/chronic liver disease and women of childbearing potential who were likely to get pregnant or were lactating were also excluded.
Results
Baseline laboratory data were checked within 72 h of starting the trial and included a haemogram, liver function Six renal transplant recipients aged 39.2±12.7 years tests, serum creatinine, and calculation of CsA area under (range 19-53 years) and 8.3±6.2 months (range 3-19 the curve (AUC ). For the latter, patients were asked to take months) after transplantation receiving the microetheir usual morning CsA dose. Blood for estimating CsA mulsified preparation of CsA (Sandimmun Neoral ) in concentration was drawn just prior to ingestion of the dose a dose of 3-6 mg/kg/day were included. Patients and subsequently at 1, 2, 4, 6 and 8 h after the dose. Patients were started on fluconazole (Flumycin, Pfizer Amboise, weighed 59.8±5.8 kg (range 57-69 kg). Three patients had oesophageal candidiasis and no other apparent individual patients. The AUC were higher by 87.48±77.65% (range 24.8-233.5%) on day 4 and cause for fever; two patients had pulmonary candidiasis, and one had cryptococcal meningitis. The mean 56.1±49.93% (range 3.5-143.3%) on day 7 as compared to day 0. After 50% reduction in CsA dosage, serum creatinine, CsA AUC, C max , C min , CsA clearance, and T max are shown in Table 1 . the AUC on day 14 were −15.70±48.29% (range −78.9 to 50.0%) different from the AUC on day 0. The mean serum creatinine increased from 139.0±30.4 mmol/l to 154.7±36.1 mmol/l on day 4 Similar inter-individual variability in percentage changes in C max , C min , and CsA clearance were seen (P<0.01) and 156.4±35.6 mmol/l on day 7 (P<0.01). There was a significant decrease in serum creatinine during the study period ( Table 2) . On factorial analysis to test for any interaction between patients with time, to 147.8±30.4 mmol/l (P<0.05) on day 14 of treatment. CsA AUC increased from 2887.8± a significant interaction was seen in AUC, C max and C min (P<0.001), suggesting thereby that each patient 1729.7 ng.h/ml on day 0 to 3842.3±1975.8 ng.h/ml on day 2 (P<0.05), 4750.5±1718.4 was behaving differently over time. Assuming an insignificant interaction with time, the main effect model ng.h/ml on day 4 (P<0.01) and declined to 4052.0±1687.9 ng.h/ml on day 7 (P<0.01). was used and a significant difference was observed in changes in AUC and C max during the study period Following CsA dose reduction by 50%, the mean AUC decreased significantly to 2330.8±1602.9 (P<0.001), but changes in C min and CsA clearance did not reach statistical significance (P>0.05). On ng.h/ml (P<0.01) and there was no significant difference between the mean AUC on day 0 and repeated measurement ANOVA, which controls for intra-individual variabilities, only the AUC at day 4 day 14. The C max showed a significant increase from 701.8±345.1 ng/ml on day 0 to 941.5 of fluconazole were higher from day 0 levels (P<0.001). In addition, C max on day 4 were also ±326.6 ng/ml (P<0.01) on day 4. After CsA dose reduction by 50%, the C max decreased from significantly higher than those on day 0 (P<0.01). Changes in C min and CsA clearance over time were 768.0±292.0 ng/ml on day 7 to 498.0±289.0 ng/ml on day 14, P<0.01. The mean C max on day 14 was not found to be significantly different. None of the patients developed alterations in liver function tests or significantly lower as compared to the mean C max on day 0 (P<0.05). The mean C min increased from graft dysfunction necessitating withdrawal from study protocol. 207.7±138.3 ng/ml on day 0 to 274.0±168.8 ng/ml on day 4. The C min on day 14 (174.7±123.3 ng/ml ) was significantly lower than that on day 0 (P<0.05). The Discussion mean CsA clearances on day 2 (18.3±9.4 ml/min/kg) and day 4 (13.1±4.2 ml/min/kg) were not significantly different from those on day 0 (16.9±5.2 ml/min/kg); The majority of reports describing an interaction between fluconazole and CsA are published as case however, the reduction in CsA clearance on day 7 (12.0±3.7 ml/min/kg) approached statistical signific-reports. Initial reports on this potential interaction concluded that fluconazole given orally in a dose of ance (P=0.08). There were no significant changes observed in T max . The changes in AUC in individual 100 mg/day did not have any significant interaction with CsA [12-15]. Subsequently case reports describpatients during the study period are shown in Figure 1 .
The percentage changes in AUC, C max , C min and ing an interaction with doses ranging from 100 mg [16 ] to 200 mg [17,18] started appearing. A recent CsA clearance on days 2, 4, 7 and 14 as compared to day 0 are shown in Table 2 . The AUC on day 2 showed large prospective randomized trial using fluconazole in a dose of 100 mg/day for prophylaxis against candida an increase of 40.95±33.82% over day 0; however, the percentage increase varied over 10-fold (7.1-86.6%) in infections in liver-transplant recipients failed to show any significant interaction with CsA [19] . One of the withdrawal from study protocol. There was a significant decrease in serum creatinine after 50% reduction two published studies confirming this interaction used oral fluconazole in a dose of 200 mg/day [8] but can in the CsA dosage. None of the patients developed alterations in liver function tests. be faulted for its study design, as it randomized patients to receive either fluconazole or placebo. This study Canafax et al. [8] in their study measured CsA trough levels daily during treatment with 200 mg of was done in patients receiving a non-emulsified preparation of CsA, which is known to possess marked oral fluconazole. AUC were done as baseline and after 2 weeks of fluconazole. They found that the trough inter-individual and intra-individual variability in gastrointestinal absorption and systemic bioavailability of levels started increasing by day 3 and the trough levels after a week of treatment were significantly higher than the drug [1] . These drawbacks were overcome in this study by selecting patients receiving only the micro-baseline values. In addition, the AUC after 2 weeks of fluconazole were significantly higher than the baseline. emulsified preparation of CsA (Sandimmun Neoral ) and employing a crossover study design, where patients We believe that it is possible that bioavailability (and AUC ) of CsA had increased before 7 days of treatment acted as their own controls.
In our study, we showed that mean CsA AUC in the patients studied by Canafax et al., because trough levels are a poor indicator of total bioavailincreased from day 2 onwards and peaked on day 4 of starting 200 mg of oral fluconazole. There was a ability of the drug especially when a non-emulsified preparation of CsA is used [1] . This could only have reduction in AUC on day 7 as compared to day 4, thereby raising the possibility of autoinduction of the been confirmed if AUC estimations were performed more frequently in their study. A recent study on high hepatic P-450 enzyme system. Fifty per cent reduction in CsA dose resulted in a fall in AUC to levels not dose (400 mg/day) intravenous fluconazole in six BMT recipients receiving intravenous CsA found a 21% significantly different from the baseline values. The mean C max also increased and peaked on day 4 of increase in CsA steady-state levels after about 1 week of treatment [9] . However, the authors believe that fluconazole. There was a reduction in mean C max on day 7, although this was not statistically significant. this increase in CsA levels was not of clinical significance as they did not observe any 'adverse effects' on Moreover the mean C max on day 14 were significantly lower than those on day 0. The mean C min increased renal functions during the study period. The threshold for diagnosing renal toxicity in this study was a minfrom day 0 to day 4 and the C min on day 14 were significantly lower than those on day 0. Apart from imum rise in serum creatinine more than twice the baseline value. Although this much increase in serum reduction in CsA clearance on day 7 of treatment with fluconazole that approached statistical significance, no creatinine may be 'acceptable' in BMT patients, in renal transplant recipients a much smaller rise in serum changes in this parameter were observed with time. In addition, no significant changes in T max were seen creatinine is of considerable concern to the treating physician. In our study, a slight but statistically signiduring the course of the study. Although the mean serum creatinine increased on day 4 and day 7 as ficant increase in serum creatinine levels was observed on days 4 and 7 of treatment with fluconazole, coincidcompared to day 0, none of the patients had an increase of more than 20% from baseline necessitating ing with the increments in AUC and C max of CsA.
Similar alterations in renal functions during concomitant use of CsA and fluconazole were reported by Canafax et al. [8] and others [14, 20] . The degree of interaction between fluconazole and CsA was different and unpredictable in individual patients. The peak increase in AUC over baseline varied 10-40 fold during the study period. Moreover the AUC achieved after 7 days of CsA dosage reduction by half resulted in AUC which ranged from 78.9% below the baseline to 50% above the baseline. Similar inter-individual variability in percentage changes were seen in C max , C min , and CsA clearance also. This interindividual variability in changes in AUC, C max and C min was confirmed on factorial analysis. We have also shown that in individual patients (regardless of the inter-individual variability), CsA trough levels are poor indicators of any ongoing changes in bioavailability of the drug due to an interaction with fluconazole. In this situation changes in AUC and C max are more likely to be apparent. Moreover, on repeated measurement ANOVA, which controls for intra-individual variabilities, only the AUC at day 4 of fluconazole were different from those on day 0 levels. Although bioavailability of fluconazole exceeds 90% after oral administration and is unaffected by food or gastric pH, it would have been ideal to measure fluconazole levels to control for any inter-individual variations in bioavailability of this antifungal agent. In this study, we took patients receiving only the microemulsified preparation of CsA, which possesses much less intra-individual variation in the pharmacokinetics of the drug.
Our findings support observations that CsA bioavailability has marked inter-individual variability. In addition, we believe that alterations in CsA pharmacokinetics with fluconazole also possesses marked inter-individual variations. Similar inter-individual variability in sensitivity of CsA metabolism to inhibition by fluconazole was reported in an in vitro study on human liver substrates recently [7] . Therefore, no firm recommendations can be made on empirical CsA dosage reduction when CsA treatment is combined with fluconazole in a dose of 200 mg/day. The possibility of any interaction with lower doses of fluconazole was not evaluated in the present study. Moreover, whether fluconazole used in doses more than 200 mg/day will have a greater degree of effect on CsA bioavailability was also not evaluated in this study.
We conclude that oral fluconazole given in a dose of 200 mg/day is associated with significant increase in bioavailability of CsA. The maximum effect occurs on day 4 after starting fluconazole. Changes in CsA trough levels are not sensitive enough to pick up this interaction. The increase in bioavailability of CsA is unpredictable in individual patients and no firm recommendations can be made regarding empirical dosage reduction of CsA when used in combination with fluconazole. All patients on CsA requiring fluconazole for treatment of systemic fungal infections should be monitored with AUC near day 4 of treatment to guide CsA dosage reductions. 
